As shown in the results of the current cohort, some subtypes of TILs present in the residual tumor such as CD3, CD8, and CD4, as well as CD4/FOXP3 and CD8/FOXP3 ratios, influenced survival outcomes. This evidence concerns the gene CD4 and neoplasm.